Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Having More Tender Than Swollen Joints Is Associated With Worse Patient-Reported Outcomes in Patients With Early RA.
Meng CF, Lee YC, Schieir O, Valois MF, Butler MA, Boire G, Hazlewood G, Hitchon C, Keystone E, Tin D, Thorne C, Bessette L, Pope J, Bartlett SJ, Bykerk VP; Canadian Early Arthritis Cohort Investigators. Meng CF, et al. Among authors: keystone e. J Clin Rheumatol. 2024 May 1. doi: 10.1097/RHU.0000000000002091. Online ahead of print. J Clin Rheumatol. 2024. PMID: 38689390
Having More Tender Than Swollen Joints is Associated With Worse Function and Work Impairment in Patients With Early Rheumatoid Arthritis.
Meng CF, Lee Y, Schieir O, Valois MF, Butler M, Boire G, Hazlewood G, Hitchon C, Keystone E, Tin D, Thorne C, Bessette L, Pope J, Bartlett S, Bykerk V. Meng CF, et al. Among authors: keystone e. ACR Open Rheumatol. 2024 Mar 6. doi: 10.1002/acr2.11658. Online ahead of print. ACR Open Rheumatol. 2024. PMID: 38446125 Free article.
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS, Kim B, Shin D, Park MK, Hwang JG, Kim MG, Chung H, Ghim J, Chung JY, Smolen JS, Burmester GR, Kim S, Bae Y, Jeon D, Yoo J, Yang G, Bae J, Keystone E. Yu KS, et al. Among authors: keystone e. Expert Opin Investig Drugs. 2023 May;32(5):429-439. doi: 10.1080/13543784.2023.2212155. Epub 2023 May 26. Expert Opin Investig Drugs. 2023. PMID: 37231670 Clinical Trial.
Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI).
Wong-Pack M, Hepworth E, Movahedi M, Kuriya B, Pope J, Keystone E, Thorne C, Ahluwalia V, Cesta A, Mously C, Bombardier C, Lau A, Aydin SZ. Wong-Pack M, et al. Among authors: keystone e. Rheumatol Adv Pract. 2023 Apr 26;7(2):rkad042. doi: 10.1093/rap/rkad042. eCollection 2023. Rheumatol Adv Pract. 2023. PMID: 37179654 Free PMC article.
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.
Constantin A, Caporali R, Edwards CJ, Fonseca JE, Iannone F, Keystone E, Schulze-Koops H, Kwon T, Kim S, Yoon S, Kim DH, Park G, Yoo DH. Constantin A, et al. Among authors: keystone e. Rheumatology (Oxford). 2023 Aug 1;62(8):2838-2844. doi: 10.1093/rheumatology/keac689. Rheumatology (Oxford). 2023. PMID: 36534825 Free PMC article. Clinical Trial.
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.
Solomon DH, Giles JT, Liao KP, Ridker PM, Rist PM, Glynn RJ, Broderick R, Lu F, Murray MT, Vanni K, Santacroce LM, Abohashem S, Robson PM, Fayad Z, Mani V, Tawakol A, Bathon J; TARGET Trial Consortium. Solomon DH, et al. Ann Rheum Dis. 2023 Mar;82(3):324-330. doi: 10.1136/ard-2022-223302. Epub 2022 Nov 30. Ann Rheum Dis. 2023. PMID: 36450449 Free PMC article. Clinical Trial.
441 results